ArticleMethods in enzymology2012
Oral enzyme therapy for celiac sprue.
Article in Methods in enzymology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 77 citations in OpenAlex.
- From gluten to therapeutics: molecular mechanisms of celiac disease and emerging alternatives to the gluten-free diet.Frontiers in pharmacology · 2026Review
- Translation of cell therapies to treat autoimmune disorders.Advanced drug delivery reviews · 2024Review
- Specificity Enhancement of Glutenase Bga1903 toward Celiac Disease-Eliciting Pro-Immunogenic Peptides via Active-Site Modification.International journal of molecular sciences · 2023Article
- Review
- New Developments in Celiac Disease Treatment.International journal of molecular sciences · 2023Review
- Tryptase and Exogenous Trypsin: Mechanisms and Ophthalmic Applications.Journal of inflammation research · 2023Review
- A Comprehensive Review of the Neurological Manifestations of Celiac Disease and Its Treatment.Diseases (Basel, Switzerland) · 2022Review
- Review on pediatric coeliac disease from a clinical perspective.European journal of pediatrics · 2022Review
- Analytical and functional approaches to assess the immunogenicity of gluten proteins.Frontiers in nutrition · 2022Review
- E40 glutenase detoxification capabilities of residual gluten immunogenic peptides inFrontiers in nutrition · 2022Article
- Current and emerging therapies for coeliac disease.Nature reviews. Gastroenterology & hepatology · 2021Review
- Commensal BacteriumNutrients · 2020Article
- Aqueous RAFT Synthesis of Low Molecular Weight Anionic Polymers for Determination of Structure/Binding Interactions with Gliadin.Macromolecular bioscience · 2020Article
- Gluten Degrading Enzymes for Treatment of Celiac Disease.Nutrients · 2020Review
- Molecular Properties and New Potentials of Plant Nepenthesins.Plants (Basel, Switzerland) · 2020Review
- Recent Progress and Recommendations on Celiac Disease From the Working Group on Prolamin Analysis and Toxicity.Frontiers in nutrition · 2020Review
- E40, a novel microbial protease efficiently detoxifying gluten proteins, for the dietary management of gluten intolerance.Scientific reports · 2019Article
- Insights on the Proteases Involved in Barley and Wheat Grain Germination.International journal of molecular sciences · 2019Review
- Plant Proteases: From Key Enzymes in Germination to Allies for Fighting Human Gluten-Related Disorders.Frontiers in plant science · 2019Article
- Development of wheat genotypes expressing a glutamine-specific endoprotease from barley and a prolyl endopeptidase from Flavobacterium meningosepticum or Pyrococcus furiosus as a potential remedy to celiac disease.Functional & integrative genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Celiac sprue is an inflammatory disease of the small intestine caused by dietary gluten and treated by adherence to a life-long gluten-free diet. The recent identification of immunodominant gluten peptides, the discovery of their cogent properties, and the elucidation of the mechanisms by which they engender immunopathology in genetically susceptible individuals have advanced our understanding of the molecular pathogenesis of this complex disease, enabling the rational design of new therapeutic strategies. The most clinically advanced of these is oral enzyme therapy, in which enzymes capable of proteolyzing gluten (i.e., glutenases) are delivered to the alimentary tract of a celiac sprue patient to detoxify ingested gluten in situ. In this chapter, we discuss the key challenges for discovery and preclinical development of oral enzyme therapies for celiac sprue. Methods for lead identification, assay development, gram-scale production and formulation, and lead optimization for next-generation proteases are described and critically assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.